- - -
The symposium will
present the evolution of medical cannabis including the
Avicanna-led advancements in R&D for novel cannabinoid delivery
forms and formulations in addition to enhanced access for patients
by Medical Cannabis by Shoppers.
- - -
This year's annual symposium coincides with
the expected launch of Avicanna's RHO Phyto advanced medical
cannabis products and In the wake of COVID-19, a virtual format
will be used that allows for a broader reach to global patients and
the medical community.
- - -
Leading experts in R&D and clinical development will
discuss the potential therapeutic benefits of medical cannabis to
address the importance of working with healthcare practitioners for
safe and effective dosing.
- - -
/NOT FOR DISTRIBUTION TO UNITED
STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES. ANY FAILURE TO
COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION
OF UNITED STATES SECURITIES LAWS/
TORONTO, June 22, 2020 /CNW/ - Avicanna Inc.
("Avicanna" or the "Company") (TSX: AVCN)
(OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on
the development, manufacturing and commercialization of
plant-derived cannabinoid-based products, is pleased to announce
that on July 21st, 2020 it will be hosting a
virtual symposium titled "Medical Cannabis 2.0" in partnership with
Medical Cannabis by Shoppers. Patients and health care
practitioners globally can join the virtual symposium to learn more
about the potential advantages of medical cannabis and the
advancement of product offerings including Avicanna's RHO Phyto
product offerings and advanced cannabinoid research collaboration
at the University of Toronto. In
addition, experts will discuss the pharmacology, safety, and dosing
guidelines of medical cannabis for therapeutic
conditions. This includes presentations on the, efficacy of
cannabinoids for chronic pain, anxiety, depression, and other
comorbidities as well as an overview of the patient pathway to
Medical Cannabis by Shoppers.
"In this unprecedent time, where patients and practitioners
have many questions and are seeking alternative and natural
solutions, we are pleased to welcome you all to our virtual
symposium on medical cannabis. My talk on Common Medical
Comorbidities will discuss how medical cannabis can be used for the
management of clinical conditions that have common associated
comorbidities of anxiety, depression and appetite and sleep
disorders. Alongside my colleagues and collaborators, we hope you
will find value in all our presentations and that they will provide
important information, as patients and health care practitioners
seeking to learn more about medical cannabis." – Dr. Amza Ali, Chief Medical Officer of
Avicanna
Discussions will be led by clinicians and scientists from the
Avicanna team as well as from prestigious Canadian academic and
clinical research organizations including the University of Toronto and University Health
Network's Toronto General Hospital.
The agenda for the virtual symposium is as follows:
- An Introduction to Cannabinoids and Their Pharmacology – Dr.
Ruth Ross (Professor and Chair,
Department of Pharmacology & Toxicology, Faculty of Medicine,
University of Toronto, Senior
Scientist, Campbell Family Mental Health Research Institute,
CAMH)
- Advanced Cannabinoid Research and drug development at the
University of Toronto – Dr.
Pauric Bannigan (Post-Doctoral
Fellow from Dr Christine Allen's
laboratory at the Leslie Dan Faculty of Pharmacy, University of Toronto)
- Medical Cannabis 2.0 and Avicanna's RHO Phyto product
offerings– Dr. Justin Grant
(Executive Vice President of Scientific Affairs, Avicanna)
- The Potential of Cannabinoids for Chronic Pain – Dr. Hance
Clarke (Staff Anesthesiologist
Director Pain Services, Director Good Hope Ehlers Danlos Clinic,
Medical Director of The Pain Research Unit, Department of
Anesthesia and Pain Management, Toronto
General Hospital, University Health Network, Associate Professor,
Department of Anesthesia, University of
Toronto)
- Anxiety, Depression and Other Comorbidities in Patients to be
Treated with Cannabinoids: Implications for Optimal Care – Dr.
Amza Ali (Chief Medical Officer,
Avicanna)
- An Introduction to Medical Cannabis by Shoppers Drug Mart –
Neil D'Souza (Senior Manager,
Operations, Medical Cannabis by Shoppers Drug Mart)
- The Future of Medical Cannabis Panel Discussion– (Aras Azadian, CEO of Avicanna Inc. /
Pat McCutcheon, CEO MediPharm Labs /
Kaveh Kahen, CEO of Sigma
Analytics)
To register for the virtual symposium please visit:
www.avicanna.com/symposium.
About Avicanna Inc.
Avicanna is an Ontario, Canada
based corporation focused on the development, manufacturing, and
commercialization of plant-derived cannabinoid-based products
through its two main business segments, cultivation and research
and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S.
and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's
cultivation activities. These two companies are licensed to
cultivate and process cannabis for the production of cannabis
extracts and purified cannabinoids including cannabidiol (CBD) and
tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily
conducted out of Canada at its
headquarters in the Johnson & Johnson Innovation Centre, JLABS
@ Toronto. Avicanna's scientific
team develops products, and Avicanna has also engaged the services
of researchers at the Leslie Dan Faculty of Pharmacy at the
University of Toronto for the purpose
of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities
are focused on the development of its key products, including
plant-derived cannabinoid pharmaceuticals, phyto-therapeutics,
derma-cosmetics, and Extracts (defined as plant-derived cannabinoid
extracts and purified cannabinoids, including distillates and
isolates), with a goal of eventually having these products
manufactured and distributed through various markets.
Stay Connected
For more information about
Avicanna, visit www.avicanna.com
Cautionary Note Regarding Forward-Looking Information and
Statements
This news release contains "forward-looking information"
within the meaning of applicable securities laws. Forward-looking
information contained in this press release may be identified by
the use of words such as, "may", "would", "could", "will",
"likely", "expect", "anticipate", "believe, "intend", "plan",
"forecast", "project", "estimate", "outlook" and other similar
expressions, and includes statements with respect to the ability of
the Company to successfully host a virtual symposium.
Forward-looking information is not a guarantee of future
performance and is based upon a number of estimates and assumptions
of management in light of management's experience and perception of
trends, current conditions and expected developments, as well as
other factors relevant in the circumstances, including assumptions
in respect of current and future market conditions, the current and
future regulatory environment; and the availability of licenses,
approvals and permits.
Although the Company believes that the expectations and
assumptions on which such forward-looking information is based are
reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include, but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company's annual information form
dated April 15, 2020, filed with the Canadian securities
regulators and available under the Company's profile on SEDAR
at www.sedar.com.
The statements in this press release are made as of the date
of this release. The Company disclaims any intent or obligation to
update any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
SOURCE Avicanna Inc.